Crown Bioscience

AUGUST 2, 2021

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52

Disease Drug Development Immune Response Drugs 52

DrugBank

MAY 15, 2024

The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drug research today. One approach is to look beyond the traditional drug molecule.

Small Molecule 82

Small Molecule Molecular Biology Drugs Disease 82

Drug Target Review

OCTOBER 26, 2023

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively.

Engineering 105

Engineering Virus Therapies Immune Response 105

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. They are called immune modulators because they help to minimize the effects of an overactive immune response in some COVID-19 patients.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52